Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00151060
Status:
COMPLETED
Last Update Posted:
2015-01-21
First Post:
2005-09-06
Brief Title:
Estramustine Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
Sponsor:
University of Michigan Rogel Cancer Center
Organization:
University of Michigan Rogel Cancer Center
Study Overview
Official Title:
Phase II Evaluation of Early Oral Estramustine Oral Etoposide and Intravenous Paclitaxel in Patients With Hormonally Responsive Adenocarcinoma of the Prostate
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hormonal therapy is the standard treatment for prostate cancer which has spread to other areas of the body Despite the high initial response rates to hormonal therapy the vast majority of men will develop cancer which is no longer responsive to hormone deprivation The average time for hormonal therapy to be effective is about 18 months Chemotherapy combinations which can treat the disease when it no longer responds to hormonal therapy have been developed but these treatments are not curative One of these combinations is estramustine etoposide and paclitaxel In men with far advanced disease 60 will have a decrease in their PSA Prostate Specific Antigen or shrinkage of tumors after treatment with this chemotherapy Despite this these men have all developed further disease progression requiring additional treatment One possible way to make chemotherapy more effective is to give it when the number of tumor cells is smallest and the number of cells to be killed is at a low level One situation in which this is true is when a man has responded to hormonal therapy any tumors are at their smallest size This study will test whether the addition of chemotherapy at that time will prolong the time until the cancer becomes unresponsive to hormonal therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None